ARTICLE
Election 2024: Antitrust Merger Enforcement in the US
October 23, 2024
Read time: 5 min
Read how the outcome of the 2024 US election could affect clients in the antitrust space. Partners Jon Dubrow, Greg Heltzer, and Ryan Tisch contributed their thoughts.
How would a Harris-Walz administration affect clients in your practice?
Bottom line: On the antitrust merger enforcement front overall, we would expect an approach that is relatively close to the Biden positions but moderated at the margins, and potentially a more pragmatic approach to how problematic issues are resolved.
Added context: Harris-Walz might be less aggressive on antitrust than Biden, given Harris’s California ties to Silicon Valley and the tech business. Press reports indicate that some donors are strongly opposed to Federal Trade Commission (FTC) Chair Khan continuing in that role. Some have also argued that a President Harris would be less indebted or tied to the most strongly progressive elements in the Democratic Party, and she could face a Republican Senate. Collectively, that could mean that key Department of Justice (DOJ)/FTC appointees would be less progressive than current agency leadership.
We could see some changes in approach to merger remedies, with the agencies reverting to the pre-Biden mainstream position and no longer being hostile to practical remedies (such as consent orders and divestitures to remedy competitive concerns). Based on Harris’s statements about price gouging, we would anticipate ongoing aggressive efforts to eliminate practices that could drive up prices, particularly for “kitchen table” products and healthcare.
New leadership at the agencies could also be procedurally more responsive to the needs of parties seeking merger approval (e.g., taking steps to offer more finality when merger investigations are closed).
We would expect little, if any, change in direction with respect to cartel investigations or other law enforcement actions, although it is possible that new DOJ leadership would take a softer/noncriminal approach to enforcement of the antitrust laws in labor markets.
How would a Trump-Vance administration affect clients in your practice?
Bottom line: The effect of a Trump-Vance administration is significantly harder to predict, but we would anticipate leadership changes at the FTC and DOJ, leading to meaningful policy changes. However, the administration would not be soft on antitrust.
Added context: The campaign has made few affirmative statements of economic policy related to antitrust or competition. Vance has suggested that he approves of Chair Khan’s management of the FTC, specifically including its focus on antitrust enforcement against the tech industry.
With anticipated leadership changes at the FTC and DOJ under a Trump presidency, we would expect that some of the more extreme policy positions taken by the Biden administration would be rolled back, and the 2023 Merger Guidelines would be rescinded (should Trump appoint personnel with a similar approach to antitrust law as during his prior administration). In particular, we would expect that consents and merger remedies would again be a favored merger remedy and that the FTC and DOJ would be reticent to apply some of the more aggressive and novel approaches set out in the 2023 Merger Guidelines.
Despite the changes, a Trump administration should not be perceived as being soft on antitrust. During his first administration, Trump’s nominees to the FTC and DOJ (while being recognized, longtime Republican antitrust voices) set out an enforcement platform that was more aggressive than a typical Republican administration, though far less aggressive than under the Biden administration.
With either administration, what should clients be most focused on from a regulatory and enforcement perspective?
Bottom line: We anticipate that there will be a more favorable environment for antitrust in M&A, going back to more traditional, pragmatic approaches with consent orders allowing for divestitures to solve problematic portions of transactions.
Added context: Antitrust appointments should be watched closely. Appointees will set the tone for the rollout of new Hart-Scott-Rodino filing rules, which will likely require a period of accommodation and adjustment between parties filing merger notifications and the agencies.
We further expect that certain industries might face closer scrutiny under either a Harris-Walz or Trump-Vance administration. Harris would look closely at consumer-oriented businesses perceived to have poor records on pricing or customer service. Trump would eye tech companies and companies in industries perceived to have offshored employment.

FTC Final Negative Option Rule: Changes and Impacts
ARTICLE / CLIENT ALERT
FTC Final Negative Option Rule: Changes and Impacts
October 23, 2024
Read time: 5 min
Following a multiyear process that was initiated in 2019 and considered thousands of public comments, on October 16, 2024, the Federal Trade Commission (FTC) announced its final amendments to the long-standing Negative Option Rule, now entitled the Rule Concerning Recurring Subscriptions and Other Negative Option Programs (the Rule).
As previewed in our spring 2023 overview of the proposed Rule, the FTC drafted the final revisions with the intent to combat practices – such as recurring charges and misleading cancellation policies for products or services that consumers no longer want but cannot cancel without undue difficulty – that it believes are unfair or deceptive. The FTC’s revisions to the Rule require consumer refunds for recurring subscriptions in the following circumstances:
- Where businesses are not truthful or leave out material information,
- Where consumers are billed without agreeing to pay for products/services, and
- Where sellers make it difficult – or nearly impossible – to cancel.
While the FTC ultimately did not incorporate burdensome proposed requirements for annual reminders or prohibitions on “saves”[1], the agency’s final Rule imposes significant new burdens on any company offering programs via which a seller interprets a customer’s silence, or failure to take an affirmative action, as acceptance of the offer.
- The FTC expanded the final Rule to cover all negative option marketing. Negative option programs typically fall into four categories: prenotification plans, continuity plans, automatic renewals, and free trial conversion offers. While the prior version of the Rule applied only to prenotification plans[2] for the sale of goods, the Rule is now expanded to apply to nearly all forms of negative option programs in any media – i.e., essentially, any offer or provision under which a consumer’s failure to take affirmative action, or silence, is interpreted as acceptance of the offer. The Rule applies to both business-to-business and business-to-consumer transactions.
- Sellers must disclose all material information and not mislead. Prior to enrolling consumers in any negative option plan, businesses must clearly and conspicuously disclose all material terms and conditions (namely, any provision of the product/service offering that would be considered by consumers or influence consumers’ decision to sign up). Material information – including the frequency and amount of charges, how to cancel, and key deadlines – must be located in close proximity to where the consumer consents to the negative option program and at every point of consent. All marketing representations related to the negative option program must be truthful, accurate, and easy to comprehend.
- Sellers must obtain and maintain consent. Sellers must obtain proof of consumers’ “unambiguously affirmative consent” to all negative option plans prior to charging consumers. They must also maintain such proof for at least three years from the date of consent unless “sellers can show by a preponderance of the evidence they use processes that make it technologically impossible for a consumer to purchase the good or service without consent.” While the proposed Rule required businesses to obtain consumers’ consent to the negative option feature separately from, and in addition to, consent to any other part of the transaction, the FTC elected not to incorporate a requirement for separate consent to “the rest of the transaction” into the final Rule, citing complexity and burden on businesses, along with potential consumer confusion.
- “Click to cancel.” Businesses must provide a simple way for consumers to cancel enrollment in any negative option plan. In other words, it must be as easy for consumers to cancel as it is to sign up, and cancellation must be offered via the same medium through which consumers enroll (e.g., if consumers sign up online, sellers cannot demand that they speak with a live or virtual representative to cancel).
Next Steps and Takeaways
While most of the provisions of the FTC’s final Rule will take effect 180 days after publication in the Federal Register, businesses must comply within 60 days of publication (if they have not already) with the provisions of the Rule prohibiting any misrepresentations in connection with a negative option feature, as existing law currently requires businesses to be truthful and not misleading when making marketing representations. According to the FTC, these provisions “should not impose an added time or cost burden on businesses operating lawfully.”
We anticipate that the FTC will enhance its existing enforcement and investigations into noncompliant activities. Prudent legal risk management calls for companies to evaluate current or planned offers for recurring subscriptions, or other negative option features, to determine whether they are compliant with the requirements of the new Rule. Where changes are necessary, legal counsel can help modify existing and planned programs to ensure compliance with the new provisions while preserving the effectiveness and consumer value of these offers.

Is Information Blocking Enforcement on the Horizon?
CLIENT ALERT / INFORMATION BLOCKING
Is Information Blocking Enforcement on the Horizon?
October 23, 2024
Read time: 6 min
On October 8, 2024, Micky Tripathi, the US Department of Health and Human Services (HHS) Assistant Secretary for Technology Policy (ASTP), released a blog post titled “Getting Real About Information Blocking and APIs.” In the post, Tripathi notes that ASTP is “highly concerned” about reports that developers of application programming interfaces (APIs) certified under ASTP’s Health IT Certification Program are engaging in practices that violate the Certification Program’s conditions and maintenance of certification requirements specific to certified APIs and ASTP’s information blocking regulations adopted under the 21st Century Cures Act. The blog post, which notes that ASTP has received “hundreds” of information blocking complaints, appears to be a warning to developers of health information technology certified under the Health IT Certification Program (certified health IT developers) and health care providers that enforcement of ASTP’s information blocking regulations is coming soon.
Cures Act Enforcement and Penalties
On July 3, 2023, the HHS Office of Inspector General (OIG) issued its final rule to implement OIG’s authority under the Cures Act to investigate claims of information blocking and assess civil monetary penalties of up to $1 million (subject to inflation adjustments) for information blocking violations by a certified health IT developer or a health information network or health information exchange (HIN/HIE). The effective date of the OIG final rule was September 1, 2023. For a discussion of the OIG final rule, see our Special Report. To date, OIG has not publicly released information about any investigation or enforcement action under the OIG final rule.
On July 1, 2024, HHS issued a final rule to implement the Cures Act provision establishing penalties (called “appropriate disincentives”) for certain health care providers determined by OIG to have committed information blocking. The disincentives for certain Medicare-participating hospitals and clinicians became effective July 31, 2024, while disincentives associated with the Medicare Shared Savings Program will become effective January 1, 2025. For a discussion of the appropriate disincentives final rule, see our On the Subject. To date, there have been no public reports of any OIG investigation under the appropriate disincentives final rule.
Certified API Practices Raising Concerns at ASTP
In the blog post, ASTP discusses what it considers to be the “biggest impediments to progress” on interoperability and data sharing. In ASTP’s view, these impediments are alleged “behaviors” by certified health IT developers or health care providers, as opposed to technology issues. ASTP does not address or otherwise note any explanations or potentially available defenses by certified health IT developers, their health care provider customers that deploy the certified APIs, or other stakeholders.
Specifically, ASTP names the following alleged behaviors as impediments to interoperability and data sharing:
- API documentation is unavailable or unusable. The conditions and maintenance of certification require a certified API developer to publish complete business and technical documentation via a publicly accessible hyperlink that allows any person to directly access the information without any preconditions or additional steps. According to ASTP, certified API users have alleged that the required documentation is unavailable or not usable, and is inconsistent and incomplete about access terms and conditions, fees structure, and the process to register applications.
- Third-party application developers are effectively being closed out. API users have claimed that certified API developers have conditioned API access on onerous fees and other terms prohibited by ASTP regulations, and engaged in other practices prohibited by the Certification Program.
- API users are prevented from connecting with providers. API users have alleged that “EHR systems are hidden behind generic API endpoints, making it difficult for API users to connect directly with health care systems.” ASTP also raised concerns about third-party applications being unavailable to electronic health record (EHR) systems users and third-party developers being denied the opportunity to sell their applications to EHR users.
- Third-party developers serving patients are presented with false regulatory hurdles. Third-party developers have alleged that health care providers or certified API developers require third-party developers using patient access APIs to sign HIPAA business associate agreements in order for patients to have electronic access to their information, even though the developers are not business associates because they are serving patients.
- Developers or providers fail to respond to API access requests. Certified API users have claimed that certified API developers and/or health care providers do not provide written and timely responses to denials for access to electronic health information as required by regulatory requirements.
Notably, the blog post does not address practices with respect to noncertified, proprietary APIs. The omission is consistent with ASTP’s prior statements that it is focused on standards-based technology rather than bespoke solutions.
Potential Enforcement
ASTP notes in the blog post that HHS can take action in two ways to address the certified API practices:
- ASTP may directly review certified API developers and certified health IT to assess compliance with applicable Certification Program requirements, suspend or terminate certifications of certified health IT modules, and ban developers from the Certification Program.
- OIG may investigate alleged information blocking practices by certified API developers and other actors subject to the information blocking regulations. As noted above, if OIG determines that information blocking occurred, OIG may impose civil monetary penalties on health IT developers and HIN/HIEs and refer information blocking violations by health care providers to CMS for application of appropriate disincentives.
Next Steps
Developers of certified API technology should consider the following next steps:
- Review their deployments of certified API technology to confirm compliance with the Certification Program’s conditions and maintenance of certification requirements specific to certified APIs.
- Review their certified API practices, as informed by the practices highlighted by ASTP in the blog post, to confirm compliance and to identify potential information blocking exceptions that may apply to related practices.
- Promptly evaluate and, if appropriate, address any complaints from certified API users alleging noncompliance with any certification requirements.
Health care providers should consider the following steps:
- Review their certified API practices, as informed by the practices highlighted by ASTP in the blog post, to confirm compliance and to identify potential information blocking exceptions that may apply to related practices.
- Promptly evaluate and, if appropriate, address any complaints from certified API users alleging noncompliance with any certification requirements.
For more information about how to prepare for HHS enforcement of the information blocking regulations, view our webinar titled “Information Blocking: Defense of Cures Act Investigations and Enforcement.” If you would like to evaluate your certified API compliance, contact any of the authors of this On the Subject or your regular McDermott lawyer.

The Corporate Transparency Act: Filing Deadline Fast Approaching
ARTICLE / CLIENT ALERT
The Corporate Transparency Act: Filing Deadline Fast Approaching
October 22, 2024
Read time: 9 min
The bi-partisan Corporate Transparency Act (“CTA”), which became effective on Jan. 1, 2024, by the first final rule implementing the CTA (“BOI Rule”),[1] was enacted to curb illicit finance and money laundering by providing law enforcement access to information about the ultimate individuals who beneficially own and control legal entities formed or registered to do business in the US (each, a “Reporting Company”).[2] Under the BOI Rule, Reporting Companies are required to file a beneficial ownership information report (“BOI Report”) with the US Department of the Treasury’s Financial Crimes Enforcement Network (“FinCEN”). FinCEN expects over 32 million Reporting Companies will be obligated to file a BOI Report and the reporting deadline for existing Reporting Companies is fast approaching. For more information regarding the BOI Rule, please see our prior Alerts “The Corporate Transparency Act: Key Considerations for Compliance With the Beneficial Ownership Reporting Rule” and “The Corporate Transparency Act: The Private Funds Guide to Compliance With the Beneficial Ownership Reporting Rule.”
Key Compliance Dates:
- Reporting Companies formed or registered to do business in the US before Jan. 1, 2024, must file their initial BOI Reports by Jan. 1, 2025.
- Reporting Companies formed or registered to do business in the US on or after Jan. 1, 2024, and prior to Jan. 1, 2025, will have 90 days from receiving confirmation of formation or registration to submit a BOI Report to FinCEN and entities formed or registered to do business in the US on or after Jan. 1, 2025, will have 30 days to file a BOI Report.
- Reporting Companies must submit updated or corrected BOI Reports within 30 days of (i) any change to the information previously reported in the BOI Report regarding the Reporting Company or its beneficial owners; or (ii) becoming aware (or having reason to know) of an inaccuracy regarding the information previously reported in their BOI Report.
Which Entities are Required to File BOI Reports With FinCEN?
Entities must file a BOI Report only if they meet the definition of Reporting Company and do not qualify for an exemption. Determining whether an entity has any reporting obligations or is eligible for an exemption under the BOI Rule is a fact-specific analysis, which must be determined on an entity-by-entity basis. The BOI Rule exempts 23 specific types of entities from the reporting requirements (each, an “Exempt Entity”), many of which are already subject to substantial federal and/or state regulation or already have to provide their beneficial ownership information to a governmental authority. Examples of such Exempt Entities include, but are not limited to, the following:
- Large Operating Companies– Entities (i) with more than 20 full-time employees in the US; (ii) that have filed a federal tax return demonstrating more than $5 million in gross receipts or sales from US sources in the prior year; and (iii) that have an operating presence at a physical office in the US.
- SEC Reporting Issuers– All SEC reporting issuers under Section 12 or 15(d) of the Securities Exchange Act of 1934 Act (“1934 Act”).
- SEC Registered Investment Advisers– Investment advisers registered with the SEC under the Investment Advisers Act of 1940 (“Advisers Act”).
- Venture Capital Fund Advisers– Investment advisers that are exempt from registration under Section 203(l) of the Advisers Act because they advise solely one or more “venture capital funds” (as defined in Rule 203(l)-1 of the Advisers Act).
- Investment Companies– Investment companies registered with the SEC under the Investment Company Act of 1940 Act (e.g., mutual funds).
- Pooled Investment Vehicles– Any “pooled investment vehicle” that is operated or advised by certain other exempt entities, namely, a bank, credit union, SEC-registered broker-dealer in securities, SEC-registered investment company, SEC-registered investment adviser or venture capital fund adviser.[3]
- Registered Broker-Dealers – Broker-dealers registered with the SEC under the 1934 Act.
- Tax Exempt Entities – Any (a) organization defined in Section 501(c) and exempt from tax under Section 501(a) of the Internal Revenue Code, (b) a political organization defined in Section 527(e)(1) and exempt from tax under Section 527(a) of the Internal Revenue Code, or (c) a trust defined in paragraph (1) or (2) of Section 4947(a) of the Internal Revenue Code.
- Subsidiaries of Certain Exempt Entities– Any entities whose ownership interests are controlled or wholly owned, directly or indirectly, by one or more qualified exempt entities.
What Information Must Be Included on a BOI Report?
Reporting Company. An entity that meets the definition of Reporting Company and is not otherwise an Exempt Entity must report information on itself and the personal information of each Beneficial Owner. Importantly, Reporting Companies formed or registered on or after Jan. 1, 2024, must also report to FinCEN information regarding individuals identified as Company Applicants.
Beneficial Owners. The BOI Rule defines a Beneficial Owner as any individual, who directly or indirectly:
- Exercises substantial controlover the Reporting Company; or
- Owns or controls 25 percent or more of the ownership interestsof the Reporting Company.
An individual exercises substantial control over a Reporting Company if the individual:
- Is a senior officer of the Reporting Company (i.e., president, CEO, COO, CFO or general counsel or any other individual who lacks the formal title but performs a similar function);
- Has the authority to appoint or remove a senior officer or a majority of the board of directors (or similar body) of the Reporting Company;
- Directs, determines or has substantial influence over important decisions made by the Reporting Company, including decisions regarding the Reporting Company’s business, finance or structure; or
- Has any other form of substantial control over the Reporting Company, such as through (a) board representation,[4] (b) ownership or control of a majority of the voting power, (c) rights associated with any financing arrangement or interest in a Reporting Company or (d) voting rights and control over intermediary entities that exercise substantial control over the Reporting Company.[5]
Company Applicants. The BOI Rule defines Company Applicant as the individual(s) who: (1) directly files the document (physically or electronically) with a secretary of state or similar office that forms or registers the entity to do business in the US; or (2) is primarily responsible for directing or controlling the filing of the formation document or first registration document. If more than one individual is involved in the filing of the document that created or registered the Reporting Company, then two individuals (but no more) must be reported as Company Applicants.
Exclusions to the Definition of Beneficial Owner. The BOI Rule contains five exceptions to the definition of Beneficial Owner: (1) a minor child, provided that a parent’s or guardian’s information is reported; (2) an individual acting as nominee, intermediary, custodian or agent on behalf of another individual; (3) an individual acting solely as an employee of a Reporting Company (provided that the employee is not a Senior Officer); (4) an individual whose only interest in a Reporting Company is a future interest through a right of inheritance; and (5) a creditor of a Reporting Company.
What Information Needs To Be Reported?
|
Reporting Company |
Beneficial Owner | Company Applicant |
|
|
|
Where to File a BOI Report?
To file a BOI Report, please visit FinCEN’s online portal, accessible here.
What are the Penalties for Non-Compliance?
Any willful failure to comply with the CTA’s reporting requirements may result in criminal and/or civil penalties, including fines of $500 per day (not to exceed $10,000) and up to two years in prison. Persons that cause a Reporting Company to fail to file or to file a false or incomplete BOI Report may also be liable for civil or criminal penalties.
Given the fast-approaching deadline to file BOI Reports for Reporting Companies created or registered prior to Jan. 1, 2024, entities should assess their BOI Report filing obligations and file any required BOI Report if they have not already done so.
Authored by Melissa G.R. Goldstein, Michael S. Didiuk, Betty Santangelo, Jessica Romano, Kyle B. Hendrix, Jonice Q. Jackson and Matthew I. Schecter.
For assistance in navigating the the CTA’s reporting requirements, please contact one of the authors or your attorney at Schulte Roth & Zabel.
[1] 31 C.F.R. § 1010.380; Final Rule, Beneficial Ownership Information Reporting Requirements, 87 Fed. Reg. 59498 (Sept. 30, 2022), available here.
[2] Other types of legal entities, including certain trusts, are excluded from the definition of Reporting Company to the extent that they are not created by the filing of a document with a secretary of state or similar office.
[3] As used in this exemption, the term “pooled investment vehicle” means any (i) any investment company, as defined in Section 3(a) of the Investment Company Act of 1940; or (ii) any company that: (A) would be an investment company under Section 3(a) but for the exclusion provided by Section 3(c)(1) or Section 3(c)(7); and (B) is identified by its legal name by the applicable investment adviser in its Form ADV filed with the SEC or will be so identified in the next annual updating amendment to Form ADV required to be filed by the applicable investment adviser pursuant to Rule 204–1 under the Advisers Act.
[4] Not all board members have substantial control. See FinCEN, Beneficial Ownership Information Reporting, Frequently Asked Questions, FAQ D.9 (issued Sept. 29, 2023) (“Whether a particular director meets [the definition of Beneficial Owner] is a question that the reporting company must consider on a director-by-director basis.”), available here.
[5] The trustee of a trust or similar arrangement can be deemed to exercise substantial control.

Election 2024: Gender-Affirming Care in the US
ARTICLE
Election 2024: Gender-Affirming Care in the US
October 21, 2024
Read time: 5 min
Read how the outcome of the 2024 US election could affect clients in the employee benefits space (with thoughts from Partner Sarah Raaii and Counsel Alden Bianchi), along with clients in the healthcare space (with thoughts from Partner Greg Fosheim).
On the issue of gender-affirming care, how would a Harris-Walz administration affect clients in your practice?
Bottom line: A Harris-Walz administration would likely provide health plans and health plan sponsors with consistency and continuity, especially in the arena of gender-affirming care. It would continue the strides taken by the Biden-Harris administration toward reducing barriers to LGBTQI+ healthcare equity.
Added context:
Greg Fosheim, healthcare partner: Continued efforts would include defending the recently finalized Affordable Care Act (ACA) Section 1557 rules, which expanded the definition of “sex discrimination” to include gender identity and sexual orientation, against challenges and injunctions. They would also continue to intervene on behalf of families seeking access to gender-affirming care in the matter of U.S. v. Skrmetti.
Sarah Raaii, EB partner: Many health plan sponsors have felt the whiplash of the ACA Section 1557 rules, which have been repeatedly issued and invalidated by courts since 2016, and the latest iteration is no different. Shortly after the recent final Section 1557 rules were issued, parts of the rules were successfully challenged, and now health plans are left to either voluntarily comply or risk potential future penalties.
Alden Bianchi, EB counsel: A Harris-Walz administration would likely stay the course on the enforcement of the ACA, which includes the law’s insurance market reforms (e.g., bar on preexisting conditions and coverage of children to age 26, among other things).
How would a Trump-Vance administration affect clients in your practice?
Bottom line: It would be a dramatic change for health plans, as it would attempt to reduce many ACA protections, including the recent Section 1557 rules that broadly apply nondiscrimination provisions to most health plans. There would likely be a return to the limited interpretation of “sex discrimination” that the Trump-Pence administration adopted in 2020 (defining “sex discrimination” solely to reflect an individual’s sex assigned at birth), so health plans would not be subject to a federal mandate to cover gender-affirming care.
Added context:
Greg Fosheim: A Trump-Vance administration is also unlikely to continue intervening on behalf of families seeking gender-affirming care and would instead push to allow states to prohibit gender-affirming care for minors, similar to how access to reproductive health became a state-by-state decision after the Dobbs decision. This would result in a challenging patchwork of state laws for providers to navigate as parties travel across state lines or use telemedicine modalities to access gender-affirming care.
Sarah Raaii: For those reasons, we would expect to see an increased focus on travel benefits from plan sponsors that seek to continue providing coverage for gender-affirming care.
Alden Bianchi: A Trump-Vance administration would cut back on many of the ACA’s insurance reforms, which would result in the proliferation of sub-standard insurance products. While some cohort of employers might embrace these products to reduce costs, they would result in broad gaps in coverage, with the rank-and-file employees (among others) incurring substantial unreimbursed expenses.
With either administration, what should clients be most focused on from a regulatory and enforcement perspective?
Bottom line: Clients should continue efforts to comply with Section 1557 irrespective of the occupant of the Oval Office.
Added context:
Greg Fosheim: A Harris-Walz administration would continue the Biden-Harris administration’s uptick in investigating and entering into resolution agreements with entities that are noncompliant with healthcare nondiscrimination rules. But other than sex discrimination being defined to include sexual orientation and gender identity, Section 1557 has not been challenged or enjoined, and therefore the date for full compliance is rapidly approaching. Additionally, clients should be prepared to balance their duty to patients under Section 1557 with their duty to staff/workforce under rights of conscience laws should staff have a religious or moral objection to providing gender-affirming care.
Sarah Raaii: Gender-affirming care could create the same administrative and compliance challenges that health plans faced after the Dobbs decision (in determining whether and how to cover reproductive healthcare in multiple states). Health plans may again be forced to take a state-by-state approach to assessing risks associated with providing gender-affirming care, to the extent that the Section 1557 rules are modified. ERISA preemption may not be a foolproof protection for health plans and company executives who oversee health plans, in light of state criminal laws that may target parties that assist others in receiving gender-affirming care, even when traveling out of state to obtain gender-affirming care legally.
Alden Bianchi: Additionally, clients should keep an eye on the mental health parity final regulations, recently issued by the Departments of Health & Human Services, Labor, and Treasury. The costs and complexity of compliance will prove daunting, perhaps even unmanageable (thereby resulting in widespread noncompliance). Equally worrisome is the anticipated coming wave of lawsuits against employers relating to the costs of their group health plan coverage.

Election 2024: Reproductive Rights in the US
ARTICLE
Election 2024: Reproductive Rights in the US
October 21, 2024
Read time: 4 min
Sarah Raaii devotes her practice to issues impacting group health and welfare benefit plans. See her thoughts below on how the outcome of the 2024 US election could affect the way plan sponsors and employers address reproductive rights.
In regard to reproductive rights, how would a Harris-Walz administration affect clients in your practice?
Bottom line: A Harris-Walz administration would seek to restore the protections of Roe v. Wade, thereby providing health plans with clarity about their obligations to cover reproductive health and reducing plan sponsors’ concerns about the risks of providing reproductive health benefits in restrictive states.
Added context: Many plan sponsors/employers would breathe a sigh of relief if the administration protects access to fertility procedures, as fertility benefits have become a popular offering for employers looking to competitively recruit and retain talent. Most plan sponsors/employers would welcome a return to uniform federal requirements regarding reproductive health, as it would support the underlying principle of ERISA – a uniform scheme of benefits to be provided by a health plan to all its employees.
How would a Trump-Vance administration affect clients in your practice?
Bottom line: A Trump-Vance administration would likely further states’ abilities to decide what types of reproductive health are legal in their territories, including fertility treatments like IVF. For large self-funded health plans, that will result in greater administrative difficulty and increased costs.
Added context: While smaller or religious employers may appreciate the ability to cut costs and limit the benefits they provide without running afoul of federal mandates, large employers that have historically provided a greater breadth of benefits and touted their fertility and family-creation benefits would struggle.
After Dobbs, large employers have already been forced to shift strategies and implement creative solutions (such as travel benefits) to continue providing reproductive health benefits to participants in restrictive states. This need would only grow if more states are emboldened to pass restrictions on reproductive health and pursue third parties such as employers that seek to fund or assist individuals in accessing reproductive health.
With either administration, what should clients be most focused on from a regulatory and enforcement perspective?
Bottom line: Plan sponsors/employers should carefully track any federal or state efforts to either expand or restrict access to reproductive care, particularly in the arena of fertility benefits.
Added context: After Dobbs focused on access to abortion, many states have signaled that they may turn their attention to limiting fertility benefits, which often require the disposal of embryos. Depending on the election outcome, these states may either gain ground or need to battle it out in court with the federal government.
In the meantime, plan sponsors/employers should remain apprised of these challenges as they seek to continue to provide participants with competitive benefits, which often means supporting travel to states in which reproductive health is widely available. Travel benefits also carry with them legal and compliance risk, and the new administration may shed light on how to assess this risk.
Finally, to the extent that reproductive healthcare includes mental health treatment or implicates states or authorities seeking information about individuals’ reproductive healthcare, plan sponsors should ensure that they are complying with recently issued regulations on the application of HIPAA to reproductive health and mental health parity.

Election 2024: Healthcare Innovation in the US
ARTICLE
Election 2024: Healthcare Innovation in the US
October 21, 2024
Read time: 4 min
Jennifer Geetter’s practice focuses on privacy, data governance, AI, genetics, consumer health apps, and other issues at the intersection of healthcare and innovation. See her thoughts below on how the outcome of the 2024 US election could affect the healthcare space.
How would a Harris-Walz administration affect clients in your practice?
Bottom line: It would likely put to rest or delay debates about the Affordable Care Act (ACA), allowing health policy and legislation to focus on other considerations. It would also likely bring greater clarity and calm to digital health-related considerations around reproductive health, including privacy and consumer health information.
Added context: Many of the healthcare innovation legal topics that my clients are contending with are highly technical areas and appear not to be significant partisan focuses. (For example, emerging standards for healthcare information exchange, generative AI in healthcare, state and federal data privacy considerations, a raft of ransomware and critical infrastructure threats, the growing industry of consumer health data, and the expanding role of genetics in healthcare.)
A key driver on whether either election result impacts these areas will be the degree of deference and encouragement the new administration gives to federal agencies to address these issues, and whether Congress has the discipline and focus to enact legislation.
How would a Trump-Vance administration affect clients in your practice?
Bottom line: Much of the oxygen in healthcare policy debates would likely be exhausted by legislative efforts to 1) curtail or repeal the ACA and 2) further restrict access to abortion and abortifacients at the state level.
Added context: This will preoccupy both Democrats and Republicans and make it more difficult to attract sustained attention on other pressing issues.
With either administration, what should clients be most focused on from a regulatory and enforcement perspective?
Bottom line: It remains to be seen how the federal government will participate in AI regulation. There are nascent efforts within certain agencies, but there is no national response yet.
Added context: The Change Healthcare ransomware highlighted that cyber-attacks are not “only” privacy events – they can disrupt critical services such as, in this case, basic pharmacy functioning.
How the federal government responds to this reckoning is a key question. In the realm of AI, it is increasingly necessary to distinguish between the risks that can be identified and managed through strong AI development and governance programs and the risks that cannot. There are risks inherent in generative AI that require a sober, highly technical, national security-focused, multinational threat analysis response to address existential-level risks such that the hard work to implement compliance programs and safeguards is truly productive, not just performative.
I will also be watching the role of the Federal Trade Commission (FTC) vis-à-vis consumer protection carefully. The current FTC has been very active on AI, privacy, and other consumer health-related topics.

Election 2024: Artificial Intelligence in the US
ARTICLE
Election 2024: Artificial Intelligence in the US
October 21, 2024
Read time: 4 min
Shawn Helms is co-head of the Firm’s technology transactions and outsourcing practice. He has broad experience in the areas of information technology, outsourcing, blockchain, crypto, artificial intelligence (AI), digital health, and telecommunications. See his thoughts below on how the outcome of the 2024 US election could affect the AI space.
How would a Harris-Walz administration affect clients in your AI practice?
Bottom line: Clients will need to invest more in aligning their AI practices with government policies, balancing innovation with heightened regulatory scrutiny. They might need to navigate increased oversight mechanisms such as audits or certifications.
Added context: The Biden administration issued the Executive Order on Safe, Secure, and Trustworthy Artificial Intelligence in late 2023. Vice President Harris has not said anything to contradict the legislative priorities outlined in that order, which are:
- Establishing standards for AI safety and security
- Protecting Americans’ privacy
- Advancing equity and civil rights
- Supporting consumers and workers
- Promoting innovation and competition
- Advancing American leadership in AI globally
All companies should anticipate a continuation of these themes, with potential new regulations requiring greater algorithmic accountability, explainability, and compliance reporting.
Harris has said that she and President Biden “reject the false choice that suggests we can either protect the public or advance innovation.” This suggests she aims to find a middle ground between promoting AI development and implementing necessary safeguards.
How would a Trump-Vance administration affect clients in your AI practice?
Bottom line: They might focus on deregulating AI to promote innovation, giving companies more freedom in AI development. However, if Trump involves Elon Musk in his administration, Musk might steer toward more regulation.
Added context: A Trump-Vance administration could also offer incentives like tax breaks to encourage investment in AI, aiming to strengthen the US competitive edge globally. Stricter immigration policies might impact the recruitment of foreign AI talent, though exceptions could be made for highly skilled individuals. This approach could boost US companies’ growth in AI but might raise concerns over ethics, data privacy, and international compliance. The wild card is Elon Musk. Trump has expressed an interest in having Elon Musk involved in his administration. We can expect he would have a major influence on AI, which might steer the administration toward more regulation (given his stance in the past).
With either administration, what should clients be most focused on from a regulatory and enforcement perspective?
Bottom line: Under either administration, companies should focus on monitoring regulatory changes in AI to adjust their compliance strategies accordingly.
Added context: Clients need to navigate potential shifts in immigration policies that might affect the recruitment of international AI talent, possibly by investing more in domestic workforce development.
Proactively adopting strong ethical practices in AI can help build public trust, regardless of changes in federal regulations. Attention to international compliance is crucial, as divergence from global data privacy and AI standards could create market access challenges. Potential roadblocks include regulatory uncertainty, talent shortages due to immigration restrictions, and ethical concerns leading to public distrust.

2024 US Presidential Election Impact Series
ARTICLE
2024 US Presidential Election Impact Series
October 21, 2024
Read time: 2 min
In the leadup to the 2024 presidential election in the United States, read our lawyers’ takes on the legal implications of a Harris-Walz administration versus a Trump-Vance administration. With detailed Q&As, we address the following topics through November 5:
- Artificial intelligence: Q&A with Shawn Helms, partner and co-head of the Firm’s technology transactions and outsourcing practice
- Healthcare innovation: Q&A with Jennifer Geetter, partner in the Healthcare Group
- Reproductive rights and health plans: Q&A with Sarah Raaii, partner in the Employee Benefits Group
- Gender-affirming care, health plans, and healthcare equity: Q&A with Greg Fosheim, partner in the Healthcare Group; Sarah Raaii, partner in the Employee Benefits Group; and Alden Bianchi, counsel in the Employee Benefits Group
- Antitrust merger enforcement: Q&A with Jon Dubrow, Greg Heltzer, and Ryan Tisch, partners in the Antitrust Group
- Privacy: Q&A with Elliot Golding, Stephen Reynolds, David Saunders, and Alexander Southwell, partners in the Global Privacy & Cybersecurity Group

Key Features of the New EU Product Liability Directive: Increased Potential for Litigation in the Technology, Pharmaceutical and Medical Device Sectors
ARTICLE / CLIENT ALERT
Key Features of the New EU Product Liability Directive: Increased Potential for Litigation in the Technology, Pharmaceutical and Medical Device Sectors
October 21, 2024
Read time: 12 min
On October 10, 2024, the Council of the European Union adopted the new EU Directive on Liability for Defective Products (New PLD), repealing Directive 85/374/EEC (PLD), adopted in 1985.
The PLD’s objective is to provide an EU-level framework governing compensation for damages caused by defective products, with the aim being to “maintain a fair balance between the interests of consumers and producers”. The PLD Directive is based on strict (no-fault) liability, and this means that in case of a defective product, the producer has to provide compensation irrespective of whether there is negligence or fault on their part, with some specific exceptions expressly provided in the PLD, which has been implemented across EU Member States.
The EU Commission performed an evaluation process, supported by an external study, to monitor whether the PLD is still adequate and able to meet its objectives today, especially in light of new technological developments. The EU Commission’s 2022 impact assessment highlighted in particular the substantial changes to product markets due to digitalisation, including the integration of new technologies such as AI and machine learning into products and the fact that software plays a crucial role in products. However, software is not explicitly mentioned in the PLD and there is “legal uncertainty about the possibility to hold software developers strictly liable”. Additionally, in a sustainability context, the EU Commission noted that “products driven by circular business models, such as refurbished and remanufactured products, account for an increasing market share”.*
These circumstances imply increased legal uncertainty for consumers and producers regarding which economic operators in the value chain can be held liable for damage caused by defective products. Moreover, the EU Commission’s assessment noted that modern products change post-market placement more frequently, e.g. due to software updates and upgrades, security updates, the use of AI and machine learning technologies, and this makes assessing products at the point of market entry a much less useful benchmark for quality.
The New PLD therefore pursues two main policy objectives: (i) adapting the PLD to the digital age and the circular economy and (ii) reducing obstacles to making claims and to getting compensation.
These objectives made clear the need to amend the EU legislative framework in connection with product liability. Key features under the New PLD Directive include:
Extension of the Definition of ‘Product’ to Include Standalone Software, Including AI
Under Article 2 of the PLD, the term ‘product’ meant “all movables, with the exception of primary agricultural products and game, even though incorporated into another movable or into an immovable”.
The New PLD now includes “digital manufacturing files, raw materials and software”, in light of the fact that “software, such as operating systems, firmware, computer programs, applications or AI systems (…) plays an increasingly important role for product safety”, and “it is capable of causing damage through its execution”.
However, the concept of software under Article 4 does not include:
- “free and open-source software developed or supplied outside the course of a commercial activity”
- digital files (except for digital manufacturing files, which contain the functional information necessary to produce a tangible item by enabling the automated control of machinery or tools, such as drills, lathes, mills and 3D printers).
Expansion of Liable Entities
Under Article 3 of the PLD, product liability only applied to the manufacturer, the importer of the product into the European Union, and – under certain conditions – the supplier of the product.
The New PLD has included under the product liability regime almost all the players involved in both the production and distribution cycle.
Distributors can be held liable if no other liable party established within the European Union can be identified, and provided that:
- “(a) the injured person requests that distributor to identify an economic operator among those referred to in paragraph 1 [e.g. the manufacturer of the product or the component] and established in the Union, or its own distributor that supplied it with that product; and
- (b)that distributor fails to identify an economic operator or its own distributor, within one month of receiving the request referred to in point (a)”.
Moreover, service providers and online platforms are subject to liability as well.
In particular, service providers can be found liable to the extent that no importer (or authorised representative) is established in the European Union. As to online platforms, they can be considered liable where it is found that:
- they perform the role of manufacturer, importer, authorised representative, fulfilment service provider or distributor in respect of a defective product;
- they present the product or otherwise enable the specific transaction in question in a way that would lead an average consumer to believe that the product is provided either by the online platform itself or by a trader acting under its authority or control.
New Rules Providing for Disclosure of Evidence
This is one of the most important features introduced by the New PLD. Article 9 provides that, upon the request of a person (i) who is claiming compensation in proceedings before a national court for damage caused by a defective product, and (ii) who has presented facts and evidence sufficient to support the plausibility of the claim, the defendant is required to disclose the available evidence provided that such disclosure is necessary and proportionate.
In parallel, at the request of a defendant that has presented facts and evidence sufficient to demonstrate the defendant’s need for evidence for the purposes of countering a claim for compensation, the claimant is required, in accordance with national law, to disclose relevant evidence that is at the claimant’s disposal.
The court is therefore given the power to order the disclosure of evidence to overcome any information asymmetries between the parties, to therefore facilitate proof of the defect and the causal link between that defect and the damage.
Where a defendant is required to disclose information that is a trade secret or an alleged trade secret, national courts are empowered, upon a duly reasoned request of a party or ex officio, to take the specific measures necessary to preserve the confidentiality of that information when it is used or referred to in the course of (or after) legal proceedings.
Where a party is required to disclose evidence, national courts are empowered, upon a duly reasoned request of the opposing party or where the national court concerned deems it appropriate and in accordance with national law, to require such evidence to be presented in an easily accessible and easily understandable manner, if such presentation is deemed proportionate by the national court in terms of costs and effort for the required party. This will be relevant especially in connection with technology and AI tools.
In this context, the role of the judge will be clearly crucial to address the issue. The judge will have to first identify the legitimate interests of all parties concerned, including third parties, and will have to carefully evaluate the relevant document or information that should be disclosed to the counterparty.
Burden of Proof and Rebuttable Presumptions to Facilitate Claimants
Another significant change introduced by the New PLD concerns the burden of proof.
Under the PLD, the injured party has to provide evidence of both (i) the defectiveness of the product in question (ii) the damage caused and (iii) the causal link between the defect and the damage. However, due to the increasing technical and scientific complexity of products, it is often difficult for the consumer to adequately prove both the existence of defects in technological devices and the causal link between the defect and the damage.
To ease the burden of proof for the injured party Article 10 of the New Directive has introduced two rebuttable presumptions.
A rebuttable presumption of defectiveness shall be applicable where:
- the defendant fails to comply with the disclosure order under Article 9 of the New PLD Directive (see § 3) above)
- the claimant proves that the product does not comply with mandatory product safety requirements laid down in the European Union or in national law that are intended to protect against the risk of the damage suffered by the injured person (this should be read, among other things, in connection with the requirements now set under the AI Act, as far as AI products are concerned); or
- the claimant proves that the damage was caused by an obvious malfunction of the product during reasonably foreseeable use or under ordinary circumstances.
As to the casual link, this is presumed where two conditions are met, jointly:
- the product is defective; and
- the nature of the damage caused by the defect is consistent with the defect.
In addition, the national court shall presume the defectiveness of the product and/or the causal link between the defect and the damage where the following are jointly met:
- where, notwithstanding the disclosure of evidence and taking into account all relevant circumstances of the case, the claimant faces “excessive difficulties” (e.g. due to technical or scientific complexity), in being able to prove the defect of the product or the causal link between the defect and the damage, or both; and
- the claimant proves that it is likely that the product is defective or that there is a causal link between the defectiveness of the product and the damage, or both.
Exemptions from Liability and State of the Art Defence
The New PLD revised the cases where liability shall be excluded, which had included where (a) the manufacturer or importer did not place the product on the market or put it into service; (b) the distributor did not make the product available on the market; (c) it is probable that the defectiveness did not exist at the time the product was placed on the market, put into service or, in the case of a distributor, made available on the market, or that that defectiveness came into being after that moment; (d) the defectiveness is due to compliance of the product with legal requirements; (e) the objective state of scientific and technical knowledge at the time the product was placed on the market or put into service or during the period in which the product was within the manufacturer’s control was not such that the defectiveness could be discovered; (f) in the case of a manufacturer of a defective component, as referred to in Article 8(1), first subparagraph, point (b), the defectiveness of the product in which that component has been integrated is attributable to the design of that product or to the instructions given by the manufacturer of that product to the manufacturer of that component; (g) in the case of a person that modifies a product as referred to in Article 8(2), that the defectiveness is related to a part of the product not affected by the modification.
This defence under letter (e) immediately above is particularly relevant, but it does not apply in certain cases, such as when the defect is caused by a lack of software updates or upgrades necessary to maintain the product’s safety, or in case of substantial modification of the product.
The New PLD also allows Member States to exclude this defence. If so, manufacturers may be held liable even if they can prove that the defectiveness could not be discovered due to the state of art at the time.
Limitation Period and (Extended) Expiry Period
The New PLD confirms the 3-year limitation period, which starts from the day on which the injured person became aware, or should reasonably have become aware, of: (a) the damage; and (b) the defectiveness; and (c) the identity of the relevant economic operator that could be held liable for that damage.
However, significant changes have been made to the 10-year expiry period, especially in connection to modified products. In fact, an injured person is no longer entitled to compensation pursuant to the New PLD upon the expiry of a period of 10 years, unless it has, in the meantime, initiated proceedings against an economic operator, and the starting date of the expiry period is:
-
(a) the date on which the defective product which caused the damage was placed on the market or put into service; or
(b) in the case of a substantially modified product, the date on which that product was made available on the market or put into service following its substantial modification.
Moreover, the expiry period is extended to 25 years where an injured person has not been able to initiate proceedings within the above-mentioned standard 10-year term, due to the latency of a personal injury.
Conclusion and Key Takeaways
The New PLD will enter into force on the twentieth day following that of its publication in the Official Journal of the European Union and must be implemented by EU Member States within two years.
The combination of the new presumptions (on product defects and causation link) and the extensive disclosure obligations, together with the inclusion of new subjects potentially liable would likely increase litigation risk for companies. This is especially true in the pharmaceutical and medical device sector (also in light of the extended expiry period, in case of latent damages) as well as in the technology sector.
The data collected from previous experience with the PLD, reveals that:
- Four product categories are more frequently subject to product liability claims: raw materials (21,2%), pharmaceutical products (16,1%), vehicles (15.2%), and machineries and mechanical appliances (12.4%); and the analysis of case law show that 67% of CJEU decisions on product liability concern pharmaceutical products and medical devices;
- The most frequent reason for rejecting a claim for a defective product concerns the burden of proof, and specifically the proof of the defect and of the link between defect and damage (these two instances together account for 53% of the rejected cases);
- The burden of proof is particularly difficult in the medical/pharmaceutical sector (including in terms of costs for collecting sufficient and valuable evidence).
One of the key features of the New PLD are mechanisms which render it easier for plaintiffs to collect evidence in areas of great complexity from a scientific and technological standpoint.
Companies – especially those operating in the above-mentioned sectors – will thus need to face this increased litigation risk and set appropriate countermeasures, including:
- Monitoring the implementation of the New PLD at Member States level
- Assessing whether they fall into one of the (expanded) categories of potentially liable subjects
- Analyzing their liability risks and preparing for the legislative changes
- Setting a strategy to counter requests for disclosures, which pose significant risk in terms of confidential information
- Revising contracts with suppliers and distributors to ensure that the risks are appropriately allocated.
*Trainee Arcangela Gerbino also contributed to this article